7th Annual

Inflammation Inhibitors

Small Molecule and Macrocyclic Approaches

April 19-20, 2016  

Inflammation Inhibitors icon

Inflammation can be the cause as well as result of a variety of medical ailments –temporary or chronic. This central role of inflammation in so many disease processes and the close connection between the immune system and inflammation, makes the inflammation field a ripe and complex area for new drug discovery, especially when it comes to small molecules that have the potential to be delivered as oral medications in a more cost-effective manner than biologics.

In its seventh year, Cambridge Healthtech Institute’s Inflammation Inhibitors meeting will continue to feature medicinal chemistry-focused case studies of small molecule drug candidates that are being tested in preclinical and early-phase clinical trials for inflammation-related conditions. Because the most recent ‘market’ successes for oral, anti-inflammatories have been against the intracellular janus kinases (JAKs), updates on progress of new and 2nd generation intra-cellular kinase inhibitor candidates will be covered. But drug leads directed against non-kinase targets such as nuclear receptors involved in innate immunity and activation of pro-inflammatory cytokines, will also be a part of the meeting. Another focus will be exploring intracellular molecules that represent good drug targets because they lie at the interface between inflammation and other diseases such as cancer and cardiovascular disease. 

We hope you can join fellow drug discovery scientists for this day-and-a-half meeting that is in the first half of our larger Drug Discovery Chemistry event.

Topics will likely include:

  • Kinase inflammation targets (JAK/STAT pathway, SYK, BTK, IRAK4, NfKB and others)
  • Innate immunity targets: TLR/RORg pathways; Th17 activation
  • New target classes: ubiquitin complexes, chaperones, lipid metabolism regulators, epigenetic modifiers
  • Intersection of inflammation and other diseases (cancer, cardiovascular disease (PCSK9 oral candidates), fibrosis, kidney disease, CNS-related conditions)

To submit a proposal to be considered for a podium presentation at the ‘Inflammation’ meeting track, please click here.

The deadline for submission is October 2, 2015

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:
Anjani Shah, Ph.D.
Conference Director
Cambridge Healthtech Institute
Phone: (914) 723-0255
Email: ashah@healthtech.com

For partnering & sponsorship information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412
Email: cbenton@healthtech.com